Rapid modification of the bone microenvironment following short-term treatment with Cabozantinib in vivo.

ABSTRACT:

Introduction

Bone metastasis remains incurable with treatment restricted to palliative care. Cabozantinib (CBZ) is targeted against multiple receptor tyrosine kinases involved in tumour pathobiology, including hepatocyte growth factor receptor (MET) and vascular endothelial growth factor receptor 2 (VEGFR-2). CBZ has demonstrated clinical activity in advanced prostate cancer with resolution of lesions visible on bone scans, implicating a potential role of the bone microenvironment as a mediator of CBZ effects. We characterised the effects of short-term administration of CBZ on bone in a range of in vivo models to determine how CBZ affects bone in the absence of tumour.

Methods

Studies were performed in a variety of in vivo models including male and female BALB/c nude mice (a

SUBMITTER: Haider MT 

PROVIDER: S-EPMC4768060 | biostudies-literature | 2015 Dec

REPOSITORIES: biostudies-literature